Breaking News Instant updates and real-time market news.

ULTA

Ulta Beauty

$238.97

2.31 (0.98%)

, PGR

Progressive

$32.37

0.7 (2.21%)

09:55
10/13/16
10/13
09:55
10/13/16
09:55

Early notable gainers among liquid option names on October 13th

Notable gainers among liquid option names this morning include Ulta (ULTA) $251.16 +12.21, Progressive (PGR) $32.33 +0.64, Baxter (BAX) $47.75 +0.76, CSX (CSX) $30.63 +0.41, and Alexion (ALXN) $120.11 +1.36.

ULTA

Ulta Beauty

$238.97

2.31 (0.98%)

PGR

Progressive

$32.37

0.7 (2.21%)

BAX

Baxter

$47.51

0.53 (1.13%)

CSX

CSX

$30.21

-0.26 (-0.85%)

ALXN

Alexion

$118.75

-3.02 (-2.48%)

  • 13

    Oct

  • 13

    Oct

  • 25

    Oct

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 07

    Dec

  • 14

    Dec

ULTA Ulta Beauty
$238.97

2.31 (0.98%)

08/26/16
DBAB
08/26/16
NO CHANGE
Target $280
DBAB
Hold
Ulta Beauty price target increased to $280 from $225 at Deutsche Bank
Deutsche Bank analyst Mike Baker said Ulta Beauty reported a "terrific" quarter by "almost any measure," but noted that expectations for the retailer have become so high that in-line to slightly better result likely aren't a major positive catalyst for the stock at current levels. Baker raised his price target on Ulta shares to $280 from $225 but keeps a Hold rating on the stock.
10/11/16
BARD
10/11/16
NO CHANGE
Target $305
BARD
Outperform
Ulta Beauty risk/reward attractive ahead of investor day, says Baird
Baird analyst Mark Altschwager previewed Ulta Beauty's investor day and said the recent pullback in the shares has lead to an attractive risk/reward for investors. The analyst expects management's tone to be upbeat, for them to update progress on long term goals, and for them to clarify revenue/unit potential, margin drivers, and supply chain initiatives. Altschwager reiterated his Outperform rating and $305 price target on Ulta Beauty shares.
08/24/16
BARD
08/24/16
NO CHANGE
Target $300
BARD
Outperform
Ulta Beauty price target raised to $300 from $280 at Baird
Baird analyst Mark Altschwager raised his price target on Ulta Beauty to $300 from $280 in anticipation of solid Q2 trends, including comps and earnings that he expects to be at least in line with consensus expectations. The analyst believes the Ulta growth story remains underappreciated by the market and that its strong management justifies its premium valuation. Altschwager reiterated his Outperform rating on Ulta Beauty shares.
08/26/16
COWN
08/26/16
NO CHANGE
Target $286
COWN
Outperform
Ulta Beauty weakness a buying opportunity, says Cowen
Cowen analyst Oliver Chen said the Street's high expectations for Ulta Beauty were likely already priced into the shares, so he recommends buying the shares on the post-earnings weakness. The analyst was most encouraged by the high same-store sales and gross margins improvement. Chen reiterates his Outperform rating and raised his price target to $286 from $265 on Ulta Beauty shares.
PGR Progressive
$32.37

0.7 (2.21%)

09/15/16
KBWI
09/15/16
UPGRADE
Target $31
KBWI
Market Perform
Progressive upgraded to Market Perform from Underperform at Keefe Bruyette
Keefe Bruyette analyst Meyer Shields upgraded Progressive to Market Perform and raised its price target to $31 from $29. The analyst believes most of the catalysts that led to increased 2016 loss ratios year-over-year have played out and rising rates and seasonality should benefit the company.
09/07/16
FBCO
09/07/16
NO CHANGE
FBCO
Progressive, U.S. Silica and Zoetis added to US Focus List at Credit Suisse
Credit Suisse added Progressive (PGR), U.S. Silica (SLCA) and Zoetis (ZTS) to the US Focus List and removed Allison Transmission (ALSN) from the US Focus List and Sealed Air (SEE) from the US Focus List and Global Focus List
06/02/16
06/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) downgraded to Neutral from Buy at BofA/Merrill with analysts led by Doug Leggate saying Exxon's strong relative performance discount's long-term oil at around $73/bbl and said shares appear to be fairly valued. 2. Intuitive Surgical (ISRG) downgraded to Neutral from Buy at Goldman with analyst David Roman saying the risk/reward looks balanced at current share levels. Roman lowered his price target for the stock to $674 from $690. 3. DeVry (DV) downgraded to Neutral from Outperform at Credit Suisse with analyst Trace Urdan saying he no longer feels confident in his investment thesis following the resignation of CFO Tim Wiggins. 4. Franklin Resources (BEN) downgraded to Sell from Neutral at UBS with analyst Brennan Hawken arguing the company is the most exposed to the Department of Labor's fiduciary rule of the names he covers given its reliance on the broker sold channel coupled with weak investment performance. He cut his price target for the shares to $28 from $39. 5. Progressive (PGR) downgraded to Sell from Neutral at Citi with analyst James Naklicki saying consensus margin and earnings expectations are too optimistic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/16
MKMP
08/08/16
NO CHANGE
MKMP
Progressive personal auto seems to be "breaking out," says MKM Partners
MKM Partners analyst Harry Fong says that Progressive's personal auto business "appears to be breaking out," as the company reported that the growth in the number of net premium it wrote accelerated to nearly 12% last quarter. The analyst says he's not concerned by the possibility of the company's combined ratio exceeding 96%, as such an increase would be in-line with its longstanding strategy. He keeps a $40 price target and Buy rating on the shares.
BAX Baxter
$47.51

0.53 (1.13%)

06/08/16
LEER
06/08/16
NO CHANGE
Target $30
LEER
Outperform
NxStage Medical competitive overhang removed, says Leerink
Leerink analyst Danielle Antalffy says Baxter (BAX) announced that it is terminating its VIVIA Home Hemodialysis program, which she believes removes a competitive overhang on NxStage Medical's (NXTM) shares and also discredits a "meaningful" driver of the bear thesis that major customers will "break up" with NxStage Medical once a competitor enters the market. The analyst sees NxStage Medical on track to deliver "solid growth," and reiterates an Outperform rating and $30 price target on its shares.
06/24/16
PIPR
06/24/16
NO CHANGE
PIPR
Medical equipment makers' exposure to U.K. 'manageable,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien estimated that the direct exposure to the U.K. of the medical equipment names in the firm's coverage with the largest Euro/Pound exposure is roughly 5%, which he believes is "manageable." The names in the space with the largest Euro/Pound exposure are Dentsply Sirona (XRAY) Cooper (COO), K2M Group (KTWO), Globus Medical (GMED), ResMed (RMD), Zimmer Biomet (ZBH), Edwards Lifesciences (EW) and Baxter (BAX), said O'Brien, who added that manufacturing may help lessen the impact for Zimmer, Edwards, Baxter and Cooper.
10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Baxter initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Baxter International with an Outperform rating and $53-$55 price target range. The analyst sees "significant balance sheet optionality" for the company to further enhance its organic growth via acquisition and/or sizeable share repurchase programs.
09/15/16
LEHM
09/15/16
INITIATION
Target $52
LEHM
Overweight
Baxter reinstated with an Overweight at Barclays
Barclays analyst Matthew Taylor reinstated Baxter International with an Overweight rating and $52 price target. The analyst sees upside to the company's long-term growth and margin targets.
CSX CSX
$30.21

-0.26 (-0.85%)

10/11/16
VERT
10/11/16
INITIATION
VERT
Hold
CSX initiated with a Hold at Vertical Research
09/13/16
09/13/16
UPGRADE
Target $35

Outperform
Follow-up: CSX upgraded on coal turnaround potential at Wolfe Research
As previously reported, Wolfe Research upgraded CSX to Outperform from Peer Perform with a $35 price target. The firm said coal headwinds are moderating and near-term coal upside given higher nat-gas prices, falling coal inventories, and expectations for a cold winter. The bank said CSX has the most turnaround potential and most leverage to improving margins, and is focused on cost reductions.
09/13/16
WOLF
09/13/16
UPGRADE
WOLF
Outperform
CSX upgraded to Outperform from Peer Perform at Wolfe Research
09/13/16
SBSH
09/13/16
NO CHANGE
Target $170
SBSH
Buy
Rails remain attractive into year-end, says Citi
Citi analyst Christian Wetherbee says he continues to view railroads as the most attractive sector within Transportation into year-end and early 2017. Rail volumes could flatten and begin to turn modestly positive by the end of 2016, which would likely extend investor rotation into the space, Wetherbee tells investors in a research note. He believes valuations in the rails sector remain attractive and that 2017 estimates are achievable. Wetherbee raised his price target for Canadian Pacific (CP) to $170 from $154, for Canadian National (CNI) to $66 from $61, for CSX (CSX) to $32 from $29, for Kansas City Southern (KSU) to $110 from $109, for Norfolk Southern (NSC) to $97 from $87 and for Union Pacific (UNP) to $106 from $100. He has Buy ratings on Canadian Pacific, CSX, Kansas City Southern and Union Pacific.
ALXN Alexion
$118.75

-3.02 (-2.48%)

09/23/16
JEFF
09/23/16
NO CHANGE
Target $120
JEFF
Hold
Alexion price target lowered to $120 from $140 at Jefferies
Jefferies analyst Eun Yang lowered her price target for Alexion Pharmaceuticals to $120 after conducting a survey of 35 U.S. hematologists/nephrologists. The survey results support a cautious outlook on Soliris sales in 2021 and beyond due to potential competition, Yang tells investors in a research note. Specifically, 60% of those surveyed will shift away from Soliris to biosimilars if they are available due to cost, Yang tells investors in a research note. The analyst keeps a Hold rating on Alexion.
10/04/16
BMUR
10/04/16
INITIATION
Target $221
BMUR
Buy
Alexion assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Alexion Pharmaceuticals with a Buy rating and $221 price target.
09/23/16
WEDB
09/23/16
INITIATION
Target $132
WEDB
Neutral
Alexion initiated with a Neutral at Wedbush
Wedbush analyst Heather Behanna initiated Alexion with a Neutral and a $132 price target.
09/26/16
LEER
09/26/16
NO CHANGE
Target $211
LEER
Outperform
Alexion to dominate terminal complement inhibitor market, says Leerink
Leerink analyst Geoffrey Porges expects Alexion's flagship complement inhibition franchise to remain the dominant, if not only, terminal complement inhibitor on the market. The analyst notes that his research finds that the number of manufacturers with competing programs in early stage development face "significant" technical and market-related challenges to match or surpass Soliris. Porges continues to view Alexion's complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases. He reiterates an Outperform rating on the stock and raised his price target on the shares to $211 from $210.

TODAY'S FREE FLY STORIES

MTN

Vail Resorts

$160.92

-1.81 (-1.11%)

20:25
12/08/16
12/08
20:25
12/08/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MON

Monsanto

$104.70

-0.71 (-0.67%)

20:17
12/08/16
12/08
20:17
12/08/16
20:17
Hot Stocks
Washington sues Monsanto over PCB contamination »

Washington Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 27

    Jan

USAC

USA Compression

$18.01

-0.14 (-0.77%)

20:15
12/08/16
12/08
20:15
12/08/16
20:15
Syndicate
USA Compression 4.5M share Spot Secondary priced at $16.25 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ICHR

Ichor Holdings

20:11
12/08/16
12/08
20:11
12/08/16
20:11
Syndicate
Ichor Holdings 5.9M share IPO priced at $9.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:53
12/08/16
12/08
19:53
12/08/16
19:53
Periodicals
YouTube-NMPA settlement estimated at over $40M, NY Times says »

The agreement between…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:46
12/08/16
12/08
19:46
12/08/16
19:46
Hot Stocks
YouTube reaches agreement to pay out unclaimed song royalties »

The National Music…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

ATH

Athene Holding

19:33
12/08/16
12/08
19:33
12/08/16
19:33
Syndicate
Athene Holding 27M share IPO priced at $40.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MMM

3M

$175.88

-0.17 (-0.10%)

19:29
12/08/16
12/08
19:29
12/08/16
19:29
Hot Stocks
3M to sell identity management business to Gemalto for $850M »

3M announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SMI

SMIC

$5.99

-0.54 (-8.27%)

19:24
12/08/16
12/08
19:24
12/08/16
19:24
Hot Stocks
SMIC announces 10-for-1 reverse stock split »

Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$62.61

0.41 (0.66%)

19:10
12/08/16
12/08
19:10
12/08/16
19:10
Hot Stocks
Ventas raises quarterly dividend 6% to 77.5c per share »

Ventas said that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:08
12/08/16
12/08
19:08
12/08/16
19:08
Periodicals
Wells Fargo chairman appointed to sales investigation committee, Reuters says »

Wells Fargo chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:03
12/08/16
12/08
19:03
12/08/16
19:03
Periodicals
Former Wells Fargo managers file suit over fake accounts, Bloomberg reports »

Three former Wells Fargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

EIX

Edison International

$69.44

-0.17 (-0.24%)

18:42
12/08/16
12/08
18:42
12/08/16
18:42
Hot Stocks
Edison International raises annual dividend 13% to $2.17 per share »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLM

PolyMet Mining

$0.87

0.0001 (0.01%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Earnings
Breaking Earnings news story on PolyMet Mining »

PolyMet Mining reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$18.38

0.18 (0.99%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Hot Stocks
Match Group launches 'Swipe Ventures,' says Tinder CEO to step down »

Match Group's Tinder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

18:18
12/08/16
12/08
18:18
12/08/16
18:18
Hot Stocks
Biogen to present aducanumab Phase 1b data at CTAD meeting »

Biogen announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

HIVE

Aerohive

$5.41

0.18 (3.44%)

18:17
12/08/16
12/08
18:17
12/08/16
18:17
Hot Stocks
Discovery Group reports 9.1% stake in Aerohive Networks, sends letter to board »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

, ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

18:05
12/08/16
12/08
18:05
12/08/16
18:05
Periodicals
Outrigger Energy nears sale to midstream services provider, Forbes says »

Private-equity backed…

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

TRGP

Targa Resources

$54.20

0.38 (0.71%)

ETP

Energy Transfer Partners

$35.13

0.55 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$78.65

0.96 (1.24%)

18:02
12/08/16
12/08
18:02
12/08/16
18:02
Hot Stocks
Post Holdings settles egg antitrust class action claims »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENZN

Enzon

$0.44

-0.0027 (-0.62%)

17:54
12/08/16
12/08
17:54
12/08/16
17:54
Hot Stocks
Icahn says enters standstill pact with Enzon »

In an amended filing on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$52.27

0.15 (0.29%)

17:53
12/08/16
12/08
17:53
12/08/16
17:53
Hot Stocks
Leidos awarded $350M government contract »

Leidos, Reston, Virginia,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:50
12/08/16
12/08
17:50
12/08/16
17:50
Hot Stocks
Dominion Diamond sees FY17 production at Ekati diamond mine 4.5M carats »

Sees FY17 Ekati diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FNSR

Finisar

$34.13

1.89 (5.86%)

, AVGO

Broadcom

$170.71

2.16 (1.28%)

17:49
12/08/16
12/08
17:49
12/08/16
17:49
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

FNSR

Finisar

$34.13

1.89 (5.86%)

AVGO

Broadcom

$170.71

2.16 (1.28%)

GLPG

Galapagos NV

$58.95

0.71 (1.22%)

XTLY

Xactly

$14.35

0.35 (2.50%)

RH

Restoration Hardware

$38.99

1.05 (2.77%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

NCS

NCI Building

$17.85

0.6 (3.48%)

FRED

Fred's

$10.84

0.15 (1.40%)

USAC

USA Compression

$18.01

-0.14 (-0.77%)

FRO

Frontline

$7.71

0.37 (5.04%)

WSM

Williams-Sonoma

$56.90

0.61 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 14

    Dec

  • 09

    Dec

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

, ANTM

Anthem

$146.61

1.41 (0.97%)

17:48
12/08/16
12/08
17:48
12/08/16
17:48
Hot Stocks
Citron's Andrew Left: 'By no means' calling Express Scripts a fraud or zero »

Speaking in a CNBC…

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

ANTM

Anthem

$146.61

1.41 (0.97%)

CVS

CVS Health

$78.11

-2.42 (-3.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:45
12/08/16
12/08
17:45
12/08/16
17:45
Earnings
Dominion Diamond reports Q3 EPS 34c with items, consensus (32c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.